The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L)1xVEGF-A bispecifics are more effective than traditional ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

SpiritMedia.US, a leading international book publishing and marketing company, celebrates the release of The Pyramid Principle by John Vallely with Paul Weissenstein on Tuesday9, 2024. The book shares ...

In draft guidance, the agency has said that while Keytruda (pembrolizumab) added to chemotherapy is more effective than chemo alone. Its long-term benefits are uncertain. Moreover, NICE says there ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication alleviates symptoms of major depression in as little as a few hours.

By The Learning Network A new collection of graphs, maps and charts organized by topic and type from our “What’s Going On in This Graph?” feature. By The Learning Network Want to learn ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.